Future pre-clinical and clinical studies evaluating the therapeutic benefit of blocking VISTA in combination with chemotherapy and/or other immune checkpoint inhibitors in pre-clinical tumour models will reveal the effect of blocking VISTA in tumour growth, metastasis and survival. Here, VSIR is linked to neoplasm.